The estimated Net Worth of Thane Wettig is at least $1.14 Milhão dollars as of 7 March 2024. Mr Wettig owns over 50,000 units of FibroGen Inc stock worth over $188,071 and over the last 4 years he sold FGEN stock worth over $365,052. In addition, he makes $583,026 as Chief Commercial Officer at FibroGen Inc.
Mr has made over 8 trades of the FibroGen Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 50,000 units of FGEN stock worth $95,500 on 7 March 2024.
The largest trade he's ever made was buying 50,000 units of FibroGen Inc stock on 7 March 2024 worth over $95,500. On average, Mr trades about 1,935 units every 25 days since 2020. As of 7 March 2024 he still owns at least 470,178 units of FibroGen Inc stock.
You can see the complete history of Mr Wettig stock trades at the bottom of the page.
Thane Wettig is the Chief Commercial Officer at FibroGen Inc.
As the Chief Commercial Officer of FibroGen Inc, the total compensation of Mr Wettig at FibroGen Inc is $583,026. There are 9 executives at FibroGen Inc getting paid more, with Kin-Hung Yu having the highest compensation of $5,856,450.
Mr Wettig is 56, he's been the Chief Commercial Officer of FibroGen Inc since . There are 15 older and 6 younger executives at FibroGen Inc. The oldest executive at FibroGen Inc is Thomas Kearns, 83, who is the Lead Independent Director.
Thane's mailing address filed with the SEC is C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO, CA, 94158.
Over the last 10 years, insiders at FibroGen Inc have traded over $188,593,537 worth of FibroGen Inc stock and bought 106,523 units worth $1,309,423 . The most active insiders traders include Rory B Riggs, Thomas B Neff, eJeffrey William Henderson. On average, FibroGen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $6,963. The most recent stock trade was executed by Deyaa Adib on 12 June 2024, trading 22,123 units of FGEN stock currently worth $25,884.
fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.
FibroGen Inc executives and other stock owners filed with the SEC include: